CYP19A1 and breast carcinoma: The combination of the aromatase inhibitor; LTZ with antiestrogen (fulvestrant) [13], multi-kinase inhibitor (sorafenib) [14], COX-2 inhibitor (celecoxib) [12], polyphenolic flavonoids (quercetin, Qu) [15] were previously studied and showed high and synergistic efficacy on the apoptosis and proliferation inhibition of breast cancer cells.